Donaustauf

Researchers are evaluating whether a preference-oriented quality of life (QoL) monitoring system with specific diagnostic and therapeutic options can improve the quality of life in patients with lung cancer during their routine follow-up care. This approach builds on previous successful studies in breast and colorectal cancer patients that showed benefits from identifying and treating QoL deficits. The study uses an electronic system tailored to lung cancer patients' and physicians' preferences to assess QoL across multiple dimensions. The study is a two-arm randomized controlled trial involving primary lung cancer patients treated at six hospitals. Participants are assigned to either an intervention group, which receives electronic QoL monitoring with real-time access to results and a multi-professional network of healthcare providers for therapy (including pain therapy, psychotherapy, social support, nutrition counseling, physiotherapy, fitness, respiratory therapy, and palliative care), or a control group, which also undergoes QoL monitoring but neither patients nor physicians see the results. Both groups have access to the therapist network. Participants complete QoL questionnaires at study entry and monthly for six months. Researchers link QoL data with clinical information from the Bavarian Cancer Registry. The main outcome is the proportion of patients needing QoL therapy in at least one area six months after starting the study. Throughout the study, patients and physicians are supported with tailored interventions, and the study monitors changes in QoL deficits to assess the effectiveness of the preference-oriented monitoring approach.

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.